Found: 10
Select item for more details and to access through your institution.
Branched Polyethylenimine-Superparamagnetic Iron Oxide Nanoparticles (bPEI-SPIONs) Improve the Immunogenicity of Tumor Antigens and Enhance Th1 Polarization of Dendritic Cells.
- Published in:
- Journal of Immunology Research, 2015, v. 2015, p. 1, doi. 10.1155/2015/706379
- By:
- Publication type:
- Article
Lenalidomide and Programmed Death-1 Blockade Synergistically Enhances the Effects of Dendritic Cell Vaccination in a Model of Murine Myeloma.
- Published in:
- Frontiers in Immunology, 2018, p. N.PAG, doi. 10.3389/fimmu.2018.01370
- By:
- Publication type:
- Article
Expanded natural killer cells potentiate the antimyeloma activity of daratumumab, lenalidomide, and dexamethasone in a myeloma xenograft model.
- Published in:
- Cancer Immunology, Immunotherapy, 2023, v. 72, n. 5, p. 1233, doi. 10.1007/s00262-022-03322-1
- By:
- Publication type:
- Article
Expansion of cytotoxic natural killer cells in multiple myeloma patients using K562 cells expressing OX40 ligand and membrane-bound IL-18 and IL-21.
- Published in:
- Cancer Immunology, Immunotherapy, 2022, v. 71, n. 3, p. 613, doi. 10.1007/s00262-021-02982-9
- By:
- Publication type:
- Article
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
- Published in:
- Cancer Immunology, Immunotherapy, 2021, v. 70, n. 1, p. 31, doi. 10.1007/s00262-020-02654-0
- By:
- Publication type:
- Article
Pilot Study: Quantitative Photoacoustic Evaluation of Peripheral Vascular Dynamics Induced by Carfilzomib In Vivo.
- Published in:
- Sensors (14248220), 2021, v. 21, n. 3, p. 836, doi. 10.3390/s21030836
- By:
- Publication type:
- Article
Potent anti-myeloma efficacy of dendritic cell therapy in combination with pomalidomide and programmed death-ligand 1 blockade in a preclinical model of multiple myeloma.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2019, v. 19, p. e163, doi. 10.1016/j.clml.2019.09.272
- By:
- Publication type:
- Article
Cytoplasmic Transduction Peptide-Fused Recombinant Tumor-Associated Antigens Can Elicit a Potent Myeloma-Specific Cytotoxic T Lymphocyte by Loading Onto Dendritic Cells.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e74, doi. 10.1016/j.clml.2017.03.134
- By:
- Publication type:
- Article
Dendritic Cell Vaccination Combined with Lenalidomide and Programmed Death-1 (PD-1) Blockade has Synergistically Induced a Marked Tumor Regression in a Murine Myeloma Model.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e86, doi. 10.1016/j.clml.2017.03.156
- By:
- Publication type:
- Article
Synergistic Antitumor Immunity by Dendritic Cells in Combination with Pomalidomide and Dexamethasone in a Murine Myeloma Model.
- Published in:
- Clinical Lymphoma, Myeloma & Leukemia, 2017, v. 17, p. e146, doi. 10.1016/j.clml.2017.03.301
- By:
- Publication type:
- Article